The New You: A Special Biotechnology Report

As corporations buy up stock in the human body, they also determine our future.

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


In 1972, when former General Electric microbiologist Ananda Chakrabarty tried to patent a microbe that could clean up oil spills, the U.S. Patent and Trademark Office denied his request. Life, the PTO told him, could not be patented.

But Chakrabarty appealed the decision, and in 1980, the Supreme Court agreed with him. “The relevant distinction [is] not between living and inanimate things,” wrote Chief Justice Warren Burger, but that microbes such as the one Chakrabarty identified are “human-made inventions.”

In making a distinction between life that stems from a natural process and life that results from a bioengineered one, the court paved the way for a heady gold rush to patent the human genome. More and more frequently, we hear of some scientist who has unlocked the delicate coding behind our most dreaded fears (breast cancer) or narcissistic obsessions (baldness).

Who owns what? Turn the page and you’ll see the anatomy of this corporate-funded new science. Produced with the reporting help of Hope Shand, research director of the pioneering biotech watchdog group Rural Advancement Foundation International, it shows just how much of the market has already been claimed by a handful of companies, most of them bankrolled by multinational pharmaceutical giants.

Biotech professionals defend patents as the only way to recoup research costs. But technology critic Jeremy Rifkin argues that such market-driven logic will only lead to a new, commercial eugenics, undoubtedly in the direction of our genetically altered centerfold. In an essay adapted from his new book, The Biotech Century, Rifkin looks beyond biotech’s beneficent promises and exposes where genetic tinkering—propelled by our own desires—is really taking us.

Fact:

In-depth journalism that investigates the powerful takes real money and is so damn important right now.But it doesn’t take a Mother Jones investigation to know that billionaires and corporations will never fund the type of reporting (like they do politicians) we do that exists to help bring about change. Instead, our mission-driven journalism is made possible by people power, and has been for 46 years now since our founding as a non-profit.

In “TITLE TK” Monica Bauerlein writes about the perilous moment we’re in, and why it’s so important that we raise $325,000 by the time November’s midterms are decided so we can be ready to throw everything we have at the big issues facing the nation no matter what happens. Please help MoJo’s people-powered journalism with a donation today.

$400,000 to go!

payment methods

Fact:

In-depth journalism that investigates the powerful takes real money and is so damn important right now.But it doesn’t take a Mother Jones investigation to know that billionaires and corporations will never fund the type of reporting (like they do politicians) we do that exists to help bring about change. Instead, our mission-driven journalism is made possible by people power, and has been for 46 years now since our founding as a non-profit.

In “TITLE TK” Monica Bauerlein writes about the perilous moment we’re in, and why it’s so important that we raise $325,000 by the time November’s midterms are decided so we can be ready to throw everything we have at the big issues facing the nation no matter what happens. Please help MoJo’s people-powered journalism with a donation today.

$400,000 to go!

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate